UPDATE: Vessix in hand, Boston Scientific targets Medtronic in high blood pressure market

Boston Scientific acquires Vessix

Boston Scientific (NYSE:BSX) is confident that it will be the 2nd player in the U.S. market for renal denervation, executives told MassDevice.com today, stressing their belief that the Vessix Vascular high blood pressure treatment acquired today is superior to competing offerings from arch-rivals Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ).

"We believe we’ll be 2nd to market with a highly differentiated technology, a true 2nd-generation device," Jeff Mirviss, president Boston’s peripheral interventions business," told MassDevice.com today.

Laguna Hills, Calif.-based Vessix makes the V2 renal denervation system. Boston Scientific agreed today to pay up to $425 million for Vessix, with a $125 million up-front payment and another $300 million in milestone payments out to 2017.

In renal denervation, the nerves lining the renal arteries, believed to play a role in high blood pressure (or hypertension), are ablated with radiofrequency energy. Dr. Keith Dawkins, global chief medical officer for Boston Scientific, told us that the procedure has proven safe and efficacious out to 3 years in clinical trials.

"The data from the interim analysis of the Vessix trial presented at TCT showed impressive reduction of both systolic pressure and diastolic pressure out to 6 months," Dawkins said.

Unlike Medtronic’s Symplicity device and its single electrode, the Vessix V2 system’s multiple electrodes fire simultaneously. St. Jude’s Enlightn device also features multiple electrodes, but they fire sequentially, not simultaneously. That means the Vessix device can accomplish the procedure in about 30 seconds, compared with up to 30 minutes for the other devices, Mirviss said.

The V2 device won CE Mark approval in the European Union in May and is also approved for the Australian market. That gives BSX a leg up in getting the device onto those markets, Mirviss said.

"That will give us an entree into literally dozens of companies around the world. We’ll be putting this into our vast distribution channel to maximize the impact of this therapy," he said. "In 2013 or early 2014, we expect to begin an [investigational device exemption] trial to work toward commercialization in the U.S. and other key geographies."

Dawkins said Boston Scientific’s internal renal denervation program will be subsumed into the Vessix operation, under the umbrella of Mirviss’ PI segment. The internal program gave BSX renal denervation knowledge that will stand it in good stead, Dawkins said.

"We’ve had an internal program for some time. We’ve learned a lot about renal denervation in general and done a lot of preclinical work. The opportunity for this, what we think is a truly differentiated product, was really too good to miss from the acquisition point of view," he said.

Several features add to that differentiation, Mirviss and Dawkins told us.

"It’s hypothesized that some of the non-responders with the Medtronic device was due to the fact that it’s uncertain that the ablation has actually occurred. This device provides direct, real-time feedback to the physician as to whether the electrodes are in contact with the vessel wall," Mirviss explained. "It also indicates whether the device is in a place it shouldn’t touch. For example in the osteum of the artery, the device will not turn on."

With reducing costs the new holy grail of healthcare, Mirviss and Dawkins said the V2 device could defray costs by reducing the incidence of the serious complications attendant to hypertension.

"Imagine a patient with very high blood pressure, uncontrolled with current medication. They are at a significantly higher risk of death, as well as a higher risk of adverse events like stroke, heart attack, heart failure and kidney failure," Mirviss said. "If we could delay or eliminate major events like strokes, heart failure or heart attacks, that will save the healthcare system a significant amount of dollars."

"You don’t have to reduce the stroke rate by very much to make a profound economic impact on healthcare costs," Dawkins added.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply